ABI-231 HCl
Product Specifications
CAS Number
2635953-17-0
Target
Others|||Microtubule Associated|||Endogenous Metabolite|||Apoptosis|||Virus Protease
Related Pathways
Cytoskeletal Signaling|||Others|||Apoptosis|||Metabolism|||Microbiology/Virology
Bioactivity
ABI-231 is a potent, orally bioavailable tubulin inhibitor that interacts with the colchicine binding site and is currently undergoing clinical trials for prostate cancer. ABI-231, has an average IC50 = 5.2 nM against panels of melanoma and prostate cancer cell lines, is orally bioavailable, and strongly suppress melanoma tumors in vivo. ABI-231 holds great promise as a new generation of orally available tubulin inhibitor.
Smiles
C(=O)(C=1NC(C=2C=3C(NC2)=CC=CC3)=NC1)C4=CC(OC)=C(OC)C(OC)=C4.Cl
Molecular Formula
C21H20ClN3O4
Molecular Weight
413.85
Shipping Conditions
Cool pack
Storage Temperature
-20°C
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1216807-01 0.02 mg (E-Coli)
Recombinant Nostoc punctiforme Putative 8-amino-7-oxononanoate synthase (bioF)
Ask
View Details 
MBS1216807-02 0.02 mg (Yeast)
Recombinant Nostoc punctiforme Putative 8-amino-7-oxononanoate synthase (bioF)
Ask
View Details 
MBS1216807-03 0.1 mg (E-Coli)
Recombinant Nostoc punctiforme Putative 8-amino-7-oxononanoate synthase (bioF)
Ask
View Details MBS1216807-04 0.1 mg (Yeast)
Recombinant Nostoc punctiforme Putative 8-amino-7-oxononanoate synthase (bioF)
Ask
View Details MBS1216807-05 0.02 mg (Baculovirus)
Recombinant Nostoc punctiforme Putative 8-amino-7-oxononanoate synthase (bioF)
Ask
View Details MBS1216807-06 0.02 mg (Mammalian-Cell)
Recombinant Nostoc punctiforme Putative 8-amino-7-oxononanoate synthase (bioF)
Ask
View Details